A new study by a University of Arkansas information systems researcher and his colleague at the University of Waikato in New Zealand shows that COVID vaccine trials conducted in geographic locations with low infection rates ...
May 24, 2022
0
105
A new method of delivering a commonly used breast cancer drug could result in considerably less time spent in hospital for some women undergoing breast cancer treatment, according to the results of a Phase 3 trial published ...
Aug 8, 2012
0
0
The development of a medicine for patients with type 1 diabetes mellitus, based on autoantigen GAD65, received a setback following crucial clinical phase 3 trials that failed to show significant effects. One possible explanation ...
Feb 1, 2012
0
0
The AIDS Clinical Trials Group (ACTG), the largest global HIV research network, which expanded its focus to conduct research into COVID-19, today announced the initiation of ACTIV-2d, a global, phase 3, multicenter trial ...
Aug 22, 2022
0
10
(HealthDay) -- Intravitreal injection of the vitreolytic agent ocriplasmin resolves vitreomacular traction and closes macular holes significantly better than placebo, but with a higher incidence of adverse events, according ...
Aug 16, 2012
0
0
(HealthDay)—A new drug significantly reduces the abdominal pain and constipation characteristic of certain types of irritable bowel syndrome, according to two new studies.
Sep 18, 2012
0
0
Results of a phase 3 trial published in The Lancet Oncology have confirmed that the drug abiraterone acetate (marketed as Zytiga) offers a significant survival benefit to patients with castration-resistant prostate cancer, ...
Sep 17, 2012
0
0
A Phase 3 clinical trial demonstrates that tofacitinib improves disease activity and inhibits progression of joint damage in rheumatoid arthritis (RA) patients who did not respond to methotrexate (MTX). Results of the 12-month ...
Jan 24, 2013
0
0
A new medication proved effective in slowing the spread of metastatic prostate cancer, while helping to maintain the quality of life, in patients with advanced disease. The phase 3 study was unblinded midway, allowing patients ...
Jun 2, 2012
0
0
Adding pertuzumab to a combination of trastuzumab and docetaxel chemotherapy extended progression-free survival by a median of 6.1 months in patients with metastatic HER2-positive breast cancer compared with patients who ...
Dec 8, 2011
0
0
